lunes, 17 de abril de 2017

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version



SECTIONS





Changes to this Summary (04/14/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that some investigators have suggested that the definition of induction failure should be expanded to include end-of-induction minimal residual disease (MRD) of more than 5%, regardless of morphologic findings (cited O'Connor et al. as reference 256).
Added text about the 16-001 (NCT03020030) trial as a prognostic risk group under clinical evaluation.
Added text to state that measurement of serum asparaginase activity (SAA) levels after a mild or questionable reaction to pegaspargase may help to differentiate patients for whom the switch to Erwinia is indicated (because of inadequate SAA) from patients for whom a change in preparation may not be necessary (cited van der Sluis et al. and Bleyer et al. as references 16 and 17, respectively).
Added text about several studies that have identified a subset of patients who experience silent inactivation of asparaginase, defined as absence of therapeutic SAA levels without overt allergy (cited Tong et al. and Vrooman et al. as references 18 and 19, respectively).
Added text to state that the authors also found that self-reporting was not a reliable measure of adherence, with 84% of patients over reporting compliance with taking mercaptopurine at least some of the time. The data suggest that additional measures of adherence besides self-reporting are needed (cited Landier et al. as reference 69).
Revised text about the COG-AALL0932 trial for standard-risk ALL.
Revised text about the COG-AALL1131 trial for high-risk and very high-risk ALL.
Added text about the COG-AALL1521 trial as a treatment option under clinical evaluation for high-risk and very high-risk ALL.
Added text about the 16-001 (NCT03020030) trial as another treatment option under clinical evaluation.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.


  • Updated: April 14, 2017

No hay comentarios:

Publicar un comentario